PGI | Jotup

Pembina Pipeline Corporation Reports Strong Results for the First Quarter 2024 and Raises Quarterly Common Share Dividend

Retrieved on:

木曜日, 5月 9, 2024

Energy, Other Energy, Utilities, Oil, Gas, Carbon, Cedar, Partnership, ARC Resources, PGI, Corporation, NGL, Web browser, ACG, Black, Tax, Emperor, WCSB, Phase, ARC, Natural gas, Transport, Engineering, NEBC, Marketing, BC Hydro, Facility, Weather, TC Energy, Ethane, RFS, Elk, Alliance Pipeline, Acquisition, Coastal GasLink Pipeline, Haisla Nation, Growth, AGM

In the first quarter of 2023, the impact of the Northern Pipeline system outage on Pipelines volumes was approximately 62 mbbls/d.

Key Points:

In the first quarter of 2023, the impact of the Northern Pipeline system outage on Pipelines volumes was approximately 62 mbbls/d.
For non-resident shareholders, Pembina's common share dividends should be considered "qualified dividends" and may be subject to Canadian withholding tax.
Further, we are pleased today to announce an increase in the quarterly common share cash dividend of 3.4 percent.
Pembina will hold an Investor Day on Thursday, May 16, 2024, in Toronto, Ontario at 6:30 a.m. MT (8:30 a.m.

THE EUROPEAN UNION (EU) Introduces the event Hellenic European Products PDO/PGI “Welcome to European table”

Retrieved on:

水曜日, 4月 24, 2024

Protected designation of origin, Wine, Safety, Marketing, Olive oil, Farmer, Agriculture, European, Food, Protection, PGI, PDO, Implementation

Building upon the success of last year's European Union (EU) campaign, which introduced the "Experience European PDO & PGI Certified Greek Products", the event marked the next chapter in the gastronomic journey.

Key Points:

Building upon the success of last year's European Union (EU) campaign, which introduced the "Experience European PDO & PGI Certified Greek Products", the event marked the next chapter in the gastronomic journey.
Guests were invited for an unforgettable evening celebrating the rich heritage and exceptional quality of European PDO & PGI-certified products.
Chef Derek Cheong, a culinary maestro, led the tasting session and also took the stage as a speaker, presenting about Greek products.
This event to introduce Greek products labeled PDO allows consumers to trust and distinguish quality products, understand the origin of products, and also help manufacturers introduce market their signature products more efficiently.

Tome Biosciences to Present Data on Programmable Genomic Integration Technologies at ASGCT

Retrieved on:

火曜日, 4月 23, 2024

Poster, Annual general meeting, PGI

WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announced that it will present preclinical data on its PGI technologies, integrase-mediated PGI (I-PGI) and ligase-mediated PGI (L-PGI), at ASGCT’s 27th Annual Meeting taking place May 7-11 in Baltimore, MD.

Key Points:

WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announced that it will present preclinical data on its PGI technologies, integrase-mediated PGI (I-PGI) and ligase-mediated PGI (L-PGI), at ASGCT’s 27th Annual Meeting taking place May 7-11 in Baltimore, MD.
The Company has been selected for an invited talk, two oral presentations and two poster presentations.
Details of Tome’s ASGCT presentations are as follows:

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

Retrieved on:

火曜日, 4月 9, 2024

MD, MIT, Patent, Composition, PASTE, PGI, DNA, State, United States patent law

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.

Key Points:

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.
This patent further protects Tome’s foundational PGI technology, integrase-mediated PGI (I-PGI), describes a system capable of performing I-PGI in a mammalian cell, and is exclusively licensed to Tome from MIT.
“Today’s issuance marks the fourth US patent granted that encompasses our I-PGI technology, strengthening our patent portfolio and broadening our exclusivity,” said Rahul Kakkar, MD, President and Chief Executive Officer of Tome.
Together, with US Patent 11,952,571, these patents cover methods and systems relating to the use of a Cas 9 nickase, reverse transcriptase and an integrase to integrate DNA sequences into programmed locations.

Premium Guard Launches Revamped Website for Interfil®

Retrieved on:

火曜日, 3月 19, 2024

PGI, Catalog, Online shopping

Interfil's new web presence highlights PGI's continued commitment to quality, innovation, and customer satisfaction in the automotive aftermarket.

Key Points:

Interfil's new web presence highlights PGI's continued commitment to quality, innovation, and customer satisfaction in the automotive aftermarket.
The refreshed design features a sleek, modern layout for a better user experience and the latest web technology for improved functionality.
The revamped website features extensive information about Interfil's high-quality products, commercial programs, solutions, and helpful technical resources for installers.
Within the new website, PGI has unveiled an enhanced Interfil® e-catalog, equipped with advanced product and application search features, designed to offer a seamless and intuitive browsing experience.

Pembina Pipeline Corporation Reports Record Results for the Fourth Quarter 2023, Provides Business Update, and Declares Quarterly Common Share Dividend

Retrieved on:

木曜日, 2月 22, 2024

Pembina reported record quarterly adjusted EBITDA of $1,033 million in the fourth quarter and record full year adjusted EBITDA of $3,824 million.

Key Points:

Pembina reported record quarterly adjusted EBITDA of $1,033 million in the fourth quarter and record full year adjusted EBITDA of $3,824 million.
Results were impacted by higher incentive costs driven by Pembina's share price performance and increased shared service revenue.
On a per share (basic) basis, cash flow from operating activities was $1.60 per share for the fourth quarter and $4.79 per share for the full year.
ET) for interested investors, analysts, brokers and media representatives to discuss results for the fourth quarter of 2023.

PGI Wins Quality Award from NAPA Auto Parts

Retrieved on:

木曜日, 3月 7, 2024

Work, Product engineering, Category, EVP, NAPA Auto Parts, PGI, NAPA, Cryptocurrency

NEW YORK, March 7, 2024 /PRNewswire/ -- Premium Guard, Inc. ( www.premiumguard.com ), an aftermarket leader and pioneer in the manufacture and supply of high-quality automotive products, was recognized by NAPA Auto Parts for its leadership and excellence in Quality.

Key Points:

NEW YORK, March 7, 2024 /PRNewswire/ -- Premium Guard, Inc. ( www.premiumguard.com ), an aftermarket leader and pioneer in the manufacture and supply of high-quality automotive products, was recognized by NAPA Auto Parts for its leadership and excellence in Quality.
The award was presented at the annual NAPA Auto Parts Supplier Partnership event where valued suppliers are recognized for their work and achievement.
"This year's recipient has gone above and beyond in delivering quality products, leading the charge in category management, and elevating overall quality standards," said Medhavin Potdar, Director of Product Engineering and Quality at NAPA Auto Parts.
"We are proud to be named among the top tier suppliers for NAPA, especially for being recognized for Quality," said Anan Bishara, PGI's founder and CEO.

Global Platinum Powder Market to Attain Revenue of $84.4 Million by 2030, Propelled by Rising Demand Across Diverse Industrial Sectors, States Kings Research

Retrieved on:

月曜日, 2月 12, 2024

On the basis of purity, the market is divided into high purity and standard purity.

Key Points:

On the basis of purity, the market is divided into high purity and standard purity.
The high purity segment is projected to account for the largest share of the platinum powder market by the end of the forecast period, reaching a valuation of USD 59.17 million by 2030.
The demand for high purity platinum powder is anticipated to witness a surge owing to its exceptional suitability for crucial applications, which, in turn, guarantees consistent and trustworthy performance.
Purchase This Comprehensive Research Report for Valuable Market Insights: https://www.kingsresearch.com/buy-now/340
The market for platinum powder is witnessing significant growth due to the increasing use of hydrogen fuel cell technology.

Global Platinum Powder Market to Attain Revenue of $84.4 Million by 2030, Propelled by Rising Demand Across Diverse Industrial Sectors, States Kings Research

Retrieved on:

月曜日, 2月 12, 2024

On the basis of purity, the market is divided into high purity and standard purity.

Key Points:

On the basis of purity, the market is divided into high purity and standard purity.
The high purity segment is projected to account for the largest share of the platinum powder market by the end of the forecast period, reaching a valuation of USD 59.17 million by 2030.
The demand for high purity platinum powder is anticipated to witness a surge owing to its exceptional suitability for crucial applications, which, in turn, guarantees consistent and trustworthy performance.
Purchase This Comprehensive Research Report for Valuable Market Insights: https://www.kingsresearch.com/buy-now/340
The market for platinum powder is witnessing significant growth due to the increasing use of hydrogen fuel cell technology.

Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors

Retrieved on:

火曜日, 1月 30, 2024

WATERTOWN, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the appointment of Daniel Curran, MD, to its Board of Directors.

Key Points:

WATERTOWN, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the appointment of Daniel Curran, MD, to its Board of Directors.
Dr. Curran was most recently Head of Rare Genetics and Hematology at Takeda Pharmaceuticals.
“Dan has a storied corporate and drug development career, stretching from his tenure at Millennium through to leadership at Takeda.
Notably, Dan oversaw the integration of Shire after its acquisition by Takeda, then leading development and execution of Takeda’s rare disease portfolio strategy,” said Rahul Kakkar, MD, President and CEO of Tome Biosciences.